Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2023-05-12 00:00:00 ET · period of report 2023-05-11 · accession 0001209191-23-029103 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-12 | 2023-05-11 | KLRS | Bornstein Jeffrey S | Dir | A - Grant | $0.00 | +35.0K | 75.2K | +87% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-11 | A | A | 35,000 | $0.00 | 75,197 | D | — | — | (F1) The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) May 11, 2024 and (ii) the next annual meeting of the Issuer's stockholders. |